Perrigo Company plc [PRGO] vs Ani Pharmaceuticals [ANIP] Detailed Stock Comparison

Perrigo Company plc

NYSE
Loading...

Ani Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Perrigo Company plc wins in 7 metrics, Ani Pharmaceuticals Inc. wins in 13 metrics, with 0 ties. Ani Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Perrigo Company plc Ani Pharmaceuticals Inc. Better
P/E Ratio (TTM) 2,818.00 24.08 Ani Pharmaceuticals Inc.
Price-to-Book Ratio 0.55 3.10 Perrigo Company plc
Debt-to-Equity Ratio 131.16 116.19 Ani Pharmaceuticals Inc.
PEG Ratio 0.91 -0.07 Perrigo Company plc
EV/EBITDA 7.26 11.46 Perrigo Company plc
Profit Margin (TTM) -33.51% 8.87% Ani Pharmaceuticals Inc.
Operating Margin (TTM) 10.20% 11.99% Ani Pharmaceuticals Inc.
EBITDA Margin (TTM) 10.20% 11.99% Ani Pharmaceuticals Inc.
Return on Equity -38.66% 16.16% Ani Pharmaceuticals Inc.
Return on Assets (TTM) 2.35% 3.82% Ani Pharmaceuticals Inc.
Free Cash Flow (TTM) $145.10M $150.90M Ani Pharmaceuticals Inc.
Dividend Yield 9.92% N/A N/A
1-Year Return -58.76% 30.56% Ani Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 0.38 2.06 Perrigo Company plc
Enterprise Value $4.93B $2.00B Perrigo Company plc
EV/Revenue Ratio 1.16 2.27 Perrigo Company plc
Gross Profit Margin (TTM) 32.64% 59.42% Ani Pharmaceuticals Inc.
Revenue per Share (TTM) $31 $44 Ani Pharmaceuticals Inc.
Earnings per Share (Diluted) $-10.12 $3.32 Ani Pharmaceuticals Inc.
Beta (Stock Volatility) 0.49 0.44 Ani Pharmaceuticals Inc.
Short % of Float 18.67% 19.22% Perrigo Company plc

Perrigo Company plc vs Ani Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

PRGO
ANIP

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Perrigo Company plc-2.64%-7.84%0.85%10.08%-16.67%-22.97%
Ani Pharmaceuticals Inc.0.75%2.70%5.49%14.02%0.96%4.92%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Perrigo Company plc-58.76%-68.05%-76.25%-88.79%-86.87%-34.15%
Ani Pharmaceuticals Inc.30.56%59.07%147.74%54.58%-9.96%3.13%

Performance & Financial Health Analysis: Perrigo Company plc vs Ani Pharmaceuticals Inc.

MetricPRGOANIP
Market Information
Market Cap i$1.61B$1.78B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i2,169,621380,535
90 Day Avg. Volume i3,503,450370,618
Last Close$10.70$82.29
52 Week Range$9.23 - $28.44$62.14 - $99.50
% from 52W High-62.38%-17.30%
All-Time High$215.73 (Apr 06, 2015)$450.00 (May 29, 2000)
% from All-Time High-95.04%-81.71%
Growth Metrics
Quarterly Revenue Growth-0.03%0.30%
Quarterly Earnings Growth-0.03%0.30%
Financial Health
Profit Margin (TTM) i-0.34%0.09%
Operating Margin (TTM) i0.10%0.12%
Return on Equity (TTM) i-0.39%0.16%
Debt to Equity (MRQ) i131.16116.19
Cash & Liquidity
Book Value per Share (MRQ)$21.33$25.81
Cash per Share (MRQ)$3.86$14.12
Operating Cash Flow (TTM) i$238.50M$185.22M
Levered Free Cash Flow (TTM) i$28.33M$119.42M
Dividends
Last 12-Month Dividend Yield i9.92%N/A
Last 12-Month Dividend i$1.16N/A

Valuation & Enterprise Metrics Analysis: Perrigo Company plc vs Ani Pharmaceuticals Inc.

MetricPRGO (Apr 24, 2026)ANIP (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i2,818.0024.08
Forward P/E i4.937.55
PEG Ratio i0.91-0.07
Price to Sales (TTM) i0.382.06
Price to Book (MRQ) i0.553.10
Market Capitalization
Market Capitalization i$1.61B$1.78B
Enterprise Value i$4.93B$2.00B
Enterprise Value Metrics
Enterprise to Revenue i1.162.27
Enterprise to EBITDA i7.2611.46
Risk & Other Metrics
Beta i0.490.44
Book Value per Share (MRQ) i$21.33$25.81

Financial Statements Comparison: Perrigo Company plc vs Ani Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPRGO (2025)ANIP (2025)
Revenue/Sales i4.25B883.37M
Cost of Goods Sold i2.76B341.31M
COGS % of Revenue i64.9%38.6%
Gross Profit i1.49B542.06M
Gross Margin i35.1%61.4%
Research & Development i95.40M51.66M
Operating Income (EBIT) i312.80M81.23M
Operating Margin i7.4%9.2%
EBITDA i637.10M174.58M
EBITDA Margin i15.0%19.8%
Pre-Tax Income i-1.30B95.79M
Pre-Tax Income % of Revenue i-30.5%10.8%
Income Tax i104.40M17.45M
Income Tax % of Revenue i2.5%2.0%
Net Income (Profit) i-1.43B78.34M
Profit Margin i-33.5%8.9%

Balance Sheet & Liquidity Metrics

MetricPRGO (2025)ANIP (2025)
Cash & Equivalents i531.60M285.59M
Total Current Assets i2.80B753.12M
Total Current Assets % of Revenue i65.8%85.3%
Total Current Liabilities i1.01B278.11M
Total Current Liabilities % of Revenue i23.8%31.5%
Long-Term Debt i3.60B599.77M
Long-Term Debt % of Revenue i84.7%67.9%
Total Shareholders Equity i2.94B540.72M
Retained Earnings i-3.68B-23.10M
Retained Earnings % of Revenue i-86.5%-2.6%
Property, Plant & Equipment i167.80M650,000

Cash Flow Statement Comparison

MetricPRGO (2025)ANIP (2025)
Operating Cash Flow i-1.06B139.39M
Operating Cash Flow % of Revenue i-24.9%15.8%
Capital Expenditures i-93.40M-13.84M
Free Cash Flow i145.10M150.90M
FCF Margin i3.4%17.1%
Debt Repayment i-34.80M-10.16M
Common Stock Repurchase iN/A-12.21M

Short Interest & Institutional Ownership Analysis

MetricPRGOANIP
Shares Short i16.69M3.58M
Short Ratio i3.999.94
Short % of Float i18.67%19.22%
Shares Outstanding i137.62M22.49M
Float Shares i136.81M19.34M
% Held by Insiders i0.41%7.37%
% Held by Institutions i115.48%99.81%
% Held by Public i-15.89%-7.18%

Dividend Analysis & Yield Comparison: Perrigo Company plc vs Ani Pharmaceuticals Inc.

MetricPRGOANIP
Last 12-Month Dividend i$1.16N/A
Last 12-Month Dividend Yield i9.92%N/A
3-Year Avg Annual Dividend i$1.12N/A
3-Year Avg Dividend Yield i1.09%N/A
3-Year Total Dividends i$3.36N/A
Ex-Dividend DateMar 02, 2026N/A